

Canakinumab allows discontinuation of corticosteroids in patients with SJIA

June 13 2013

Study findings first presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate the efficacy of canakinumab at tapering corticosteroid (CS) use in patients with SJIA.

Successful CS tapering was achieved within 20 weeks in almost half of patients (44.5%, p

Citation: Canakinumab allows discontinuation of corticosteroids in patients with SJIA (2013, June 13) retrieved 27 April 2024 from <https://medicalxpress.com/news/2013-06-canakinumab-discontinuation-corticosteroids-patients-sjia.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--